The stock of Norwegian contrast agent developer Nycomed rose on the Oslo stock exchange this month on rumors that the company was exploring closer ties with German pharmaceutical company Altana Industrie-Aktien und Anlagen. The companies are already
The stock of Norwegian contrast agent developer Nycomed rose on the Oslo stock exchange this month on rumors that the company was exploring closer ties with German pharmaceutical company Altana Industrie-Aktien und Anlagen. The companies are already jointly marketing an ulcer drug, and may be looking for ways to expand their partnership, according to AFX News.
Nycomed has been the subject of merger or acquisition rumors since its proposed merger with U.S. generic drug firm Ivax broke down in 1995 (SCAN 12/13/95). The company said at the time the deal fell apart that it would continue to pursue strategic partnerships. Nycomed executives declined to comment on the Altana rumors.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
2 Commerce Drive
Cranbury, NJ 08512